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Abstract- Purpose: To develop a clinically relevant 
porcine model for the study of hepatic metabolism of drugs 
by means of hepatic vein catheterization. 
Materials and Methods: review of literature and 
elaboration of a hypothesis, design of an experimental 
method. 
Results: recent clinical studies were conducted by 
withdrawing cirrhotic patients’ blood from right hepatic vein 
during hepatic vein pressure gradient measurements. Basing 
on our personal clinical experience and evaluation of 
research needs, an experimental model is proposed. 
Conclusions: contemporary measurement of peripheral 
and hepatic concentration of drugs by peripheral vein and 
hepatic vein catheterization can be used to create a reliable 
and reproducible porcine model to study liver metabolism of 
drugs in vivo. 







Liver is central in drug metabolism in several ways 
and, as a consequence, hepatic impairment alters drugs 
availability. Porto-systemic shunting, i.e., decreases the 
first-pass metabolism of a drug and lead to increased oral 
bioavailability of highly extracted drugs; impaired 
production of drug-binding proteins can altered 
distribution and, furthermore, the activity and capacity of 
hepatic drug metabolizing enzymes might be affected to 
various degrees in patients with acute or chronic liver 
disease. The disposition of a large number of opioid drugs, 
which are among the most important “weapons” to fight 
pain in the anaesthesiology and intensive care practice, is 
modified in the presence of hepatic impairment but the 
pharmacokinetics of phenylpiperidine opioids such as 
fentanyl, sufentanil and remifentanil appear to be 
unaffected in hepatic disease [1]. 
Since liver is the major organ of drug metabolism, 
Orthotopic Liver Transplantation (OLT), and in particular 
its anhepatic phase, provides an unique opportunity to 
determine if a drug is metabolized in other sites, such as 
the remifentanil case [2]. 
Nevertheless, OLT is time-consuming and complex. It 
has a significant influence on the body internal 
environment and on the circulation. The characteristics of 
blood loss, fluid replacement and body temperature during 
various surgical stages are different and all these factors 
may have influences on pharmacokinetic parameters. 
Another technique to study in vivo liver metabolism of 
drugs and in particularly of anaesthetics is highly 
desirable, consequently. 
For these reasons, we propose to study 
pharmacokinetic of opiods using an experimental model 
which is based on the withdrawal of blood from the 
hepatic vein, in normal and pathological conditions, 
permitting the comparison with the concentration of drugs 
in peripheral serum and the calculation of the liver 
extraction ratio.  
  
 
II. MATERIALS AND METHODS 
 
Review of literature was conducted searching 
PubMed database for the terms “hepatic vein catheter and 
drugs” (37 papers), “HVPG and drugs” (40 papers). 
All the matching papers were revised separately by 
two independent reviewers (OP, RR) who performed trial 
selection and quality assessment. 
Clinical application of the method was tested in two 
patients who required a deep sedation to perform the 
hepatic venous pressure gradient (HVPG) measurement 
and who consented to participate in a clinical research for 
remifentanil metabolism (data not published) by two 
experienced physicians (CE, EC) [3]. 
Evaluation of published experimental methods to 
measure remifentanil liver metabolism or hepatic 
extraction of other drugs was conducted searching 
PubMed database for the terms: “experimental model to 
study liver metabolism of remifentanil “ (1 paper) “and 
pig experimental model to study liver metabolism of 
drugs” (41 papers), “animal experimental model to study 
liver extraction of drugs” (23 papers). All the matching 
papers were revised separately by two independent 
reviewers (OP, GS) who selected the appropriate and 
focused scientific works. 
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We included full-text clinical trials in patients with 
cirrhosis and portal hypertension. The primary outcome 
was mean change in drug concentration between hepatic 
venous blood  and peripheral blood. From 77 citations, 2 
clinical trials [4,5] and 1 experimental paper [6] were 
included.  Data retrieved are showed in table 1. 
In two patients, who volunteered to participate a 
clinical study and who needed HVPG for their clinical 
condition, peripheral and right hepatic vein blood 
withdrawals were taken to measure remifentanil serum 
concentration before and after HVPG without any 
inconvenience. 
As already existing experimental model is concerned, 
2 papers [7,8] only fitted partially our criteria: results are 
described in table 2. Papers in which liver transplant was 
described or tissues and cells ex vivo were used, were 
excluded. 
From the exposed data, we elaborated the following 
hypothetical experimental model to realize a minimally 
invasive, repetitive method to study drug extraction rate in 
pigs and we named it ETHER (Experimental model To 
study Hepatic Extraction of Remifentanil). 
Pigs are the selected animal for this protocol, because 
of their availability and the similarity existing between 
porcine and human liver [9]. Pigs used for this protocol, 
females with a weight about 60 kg, come from authorized 
structure (Harlan, Charles River) and are carried with 
suitable means to the laboratories prepared at the research 
center about 24 hours before the beginning of the 
experimental procedures. Then every pig is subjected to a 
clinical examination to evaluate their health state. 
On the first day of the study, blood samples are 
collected to evaluate liver and renal function. Blood 
samples are collected from internal jugulair vein after an 
adequate sedation with tiletamine hydrocloride plus 
zolazepam 2,5 mg/Kg by an intramuscular injection in the 
neck region. After 10 minutes pigs are placed in dorsal 
recumbency to perform blood sampling. After overnight 
fasting, the study animal is transferred to the experimental 
OR, where X Rays, angiographic table and complete 
hemodynamic equipment is available. 
Study measurement is done under sedation and 
monitoring for vital signs (including heart rate, arterial 
blood pressures, digital oxygen saturation, and ECG). 
Periodically we monitorize: hemogasanalysis, hematocrit, 
electrolytes and glycemia. 
A possible anaesthesia protocol could by the 
following:  
1. Premedication: in the stall an intramuscular injection 
in the neck region with tiletamine hydrocloride and 
zolazepam 2,5 mg/Kg plus atropine 0,025 mg/Kg is 
performed. After 10 minutes, pigs are clean,  taken to 
the operating room by a special stretcher, and 
positioned on the operating table. 
2. Induction: in the animal in sternal recumbency an 
incannulation of the marginal ear vein is performed 
with an adequate angioacath. After an intravenous 
injection with propofol (6 mg/Kg)  plus ketamine 
hydrochloride (15 mg/kg) plus atropine sulfate (0.04 
mg/kg) and the evaluation of palpebral and lingual 
reflexes, an oro-tracheal intubation is performed. The 
correct position of the orotracheal tube is confirmed 
by the auscultation of the right and left lung fields. 
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Pigs positioned in dorsal recumbency is connected to 
the mechanical ventilator and ventilated with a 
mixture of air and oxygen (Respiratory Rate 16 
breath/minutes, Tidal Volume10ml/Kg). Under 
aseptic conditions, a venous introducer is placed in 
the right jugular or in the femoral vein using a 
combination of the cutdown procedure and 
Seldinger's technique to expose blood vessels and 
introduce the catheter [10,11].  
3. Manteinance: it is performed by continuous 
intravenous infusion of propofol (6 mg/Kg/hour) or 
inhalathor administration of isoflorane (1,2%). plus  
butorphanol (0.5 mg/kg/hour iv) plus rocuronium 
bromide (0.8 mg/kg iv) plus ketamine in bolus during 
major surgical stress. Blood volume is maintained 
with the infusion of  saline (hematocrit target 25-
40%). 
4. Recovery: After every experimental procedure, 
sedation is stopped and animals are positioned in 
sternal recumbency. After the reversion of palpebral 
and mastication reflexes and of spontaneus breath, 
animals are estubated and returned to their stall, 
where they are monitorized with water and food 
available, soft lighting, and an ambient temperature 
and humidity of 22+/- 2% and 55+/- 10% . 
5. Euthanasia: after all the experiments animals are 
sacrificed by the intravenus injection with  
embutramide 200 mg plus mebenzonio iodide 50 mg 
plus tetracaine hydrochloride 5 mg (3 ml/10 kg). 
During the procedure pigs are sedated and connected 
to a mechanical ventilator. 
With the introducer in place, a 5-French balloon 
tipped catheter (Swan-Ganz) is advanced through it under 
fluoroscopic guidance and hooked into a hepatic vein. 
Once the tip of the catheter is inside the main right hepatic 
vein the position of catheter and caliber of vein is 
confirmed by injection of contrast.  
Free (FHVP) and wedged hepatic venous pressure 
(WHVP) are measured and recorded and the hepatic 
venous pressure gradient (HVPG) is calculated.  
Just before these measurements, 5 ml of blood is 
drawn from a main hepatic vein and peripheral vein (PV) 
and analysed successively to measure plasma remifentanil 
concentration -or other drugs, administered by bolus or 
continuous infusion-, and allow metabolomics profiling. 
Plasma samples are collected for determination of 
pharmacokinetic (including the hepatic extraction ratio) 
and pharmacodynamic (reflected in increases in 
remifentanilic acid levels, the main metabolite of 
remifentanil) characteristics of remifentanil.  
The extraction ratio of remifentanil is determined as 
(peripheral vein plasma concentration–hepatic vein 
plasma concentration) / (peripheral vein plasma 
concentration).  
Quantification of remifentanil in opportunely 
prepared plasma samples is performed by liquid 
chromatography coupled to tandem mass spectrometry 
(LC-MS/MS) [12]. 
Hepatic blood flow (HBF) will be measured using the 






Remifentanil has been selected as model drug to 
explore the concept of drug metabolism independent of 
liver function. 
Remifentanil is a synthetic μ-opioid agonist; although 
chemically related to the fentanyl family of short-acting 4-
an-ilidopoperidine derivatives, remifentanil is structurally 
unique among currently commercially available opioids 
secondary to an ester-linkage that is crucial to its opioid 
activity. Unlike other opioid analogs, it is susceptible to 
ester hydrolysis by blood and tissue esterases. This gives 
it an “ultra-short” duration of action and makes its 
elimination virtually independent on hepatic or renal 
function [13]. 
Its pharmacokinetic characteristics for what concerns 
hepatic metabolism have been explored in mainly during 
liver transplant [2]. 
Starting from this consideration we elaborated an 
experimental model, which we are going to submit to the 
animal studies ethical committee evaluation, that has the 
characteristic to be easier than an “anhepatic”phase of a 
transplant model and less invasive than a laparotomic 
cannulation of hepatic vein. 
Obviously, many other drugs, which hepatic 
metabolism is currently under study, could be approached 
by this method and it could allow researchers to test liver 
metabolism of drug in different clinical settings. In critical 
care research, i.e., would be very interesting to study 
drugs pharmacokinetics in sepsis [14,15] or in severe 
hypotensive states [16], which are among the underlying 
conditions [17-19] to the administration of sedative drugs. 
Nevertheless, we realize that our experimental model 
presents some difficulties, such as vein cannulation. 
The external jugular veins of swine are located at the 
same tissue depth as the internal jugular veins and carotid 
sheath. The depth of their location makes identification of 
them difficult. Femoral access is generally gained by 
surgical incision: we propose a combination of incision 
and percutaneous approach, with Doppler guide. 
Tunnelling of the catheter is auspicable for repeated 
measures: if the catheter is tunnelled, is it possible to 
repeat measures and withdrawals for many days or with 
different drugs, minimizing costs and avoiding sufferance 
to the experimental animals. Catheter access should be 
located on the dorsum of the body to prevent trauma but 
Swan Ganz catheter are not designed for tunnelisation. 
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This experimental model needs to be tested: in the 
mean while we are looking for other minimally invasive 
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